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Abstract
Background: Ovarian cancer has the highest mortality rate of the three main malignant tumors of the female
reproductive system, with a 5-year overall survival (OS) of only 20–30 %. Approximately 70 % of patients relapse
without being cured. To explore the significance of serum CA125 level pre-treatment and the change pattern of
CA125 post-treatment for judging prognosis and diagnosing recurrences of epithelial ovarian cancer (EOC).
Methods: A radioimmunoassay was used to continuously monitor levels of serum CA125 in 152 patients with EOC.
The first test was done before surgery, then once a month after surgery for more than two consecutive years. The
data were analyzed by using Kaplan-Meier curves and the log-rank test, stratified chi-square test, Pearson correlation
analysis, and multivariate Cox regression analysis.
Results: (1) There was a relationship between patient outcomes and the serum CA125 levels before treatment and
the extent and speed of serum CA125 decrease after treatment. The outcomes of patients with pre-treatment
serum CA125 ≤ 35 U/ml were better than those with serum CA125 > 35 U/ml; the outcomes of patients with serum
CA125 who had a logarithmic decrease or a decrease to normal within a month after treatment were also better
than those with a non-logarithmic decrease or a decrease to normal that took longer than a month. (2) The results
of multivariate Cox regression analysis showed that serum CA125 levels before treatment and a decreased speed of
decline after treatment were independent prognostic factors; (3) The mean level of serum CA125 at relapse was
116.28 U/ml. The average time from serum CA125 increase to detection of a recurrent lesion by physical or imaging
examination was 122 days. The correlation coefficient of serum CA125 level increase and tumor recurrence time
was −0.674. (4) The area under the Receiver Operating Characteristic (ROC) curve of serum CA125 for diagnosing
EOC recurrence was 0.879, and the sensitivity and specificity were 67.39 and 86.79 %, respectively.
Conclusions: It is important to monitor serum CA125 levels pre-treatment and the change pattern of CA125
post-treatment for judging prognosis and diagnosing recurrences of EOC.
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Background
Ovarian cancer has the highest mortality rate of the
three main malignant tumors of the female reproductive
system, with a 5-year OS of only 20–30 % [1]. The early
stages of ovarian cancer have no overt or classical clin-
ical symptoms and most patients are diagnosed in ad-
vanced stages, so clinical treatment and prognosis are
not satisfactory. Approximately 70 % of patients relapse
without being cured. Early diagnosis of recurrences of
EOC has great significance for its treatment and progno-
sis. This article retrospectively evaluates the change pat-
tern of serum CA125 level during the whole treatment
process of EOC patients, analyzes the relationship be-
tween patient’s disease status and the level of serum
CA125, and explores the significance of the change pat-
tern of serum CA125 level for judging prognosis and
diagnosing recurrences of EOC.
Methods
Clinical data of cases
Subjects
A total of 152 patients with ovarian cancer treated at
our hospital from January 2005 to December 2011 were
included in the study. Diagnoses of all patients were
confirmed by histopathology. All patients were treated
primarily with optimal cytoreductive surgery (hysterec-
tomy, bilateral salpingo-oophorectomy, omentectomy,
pelvic lymph node dissection, and para-aortic lymph
node dissection at the level of the inferior mesenteric ar-
tery, and appendectomy for mucinous carcinoma)
followed with platinum-based chemotherapy for 6 to
8 cycles. All patients had clinical complete remission
after primary surgery and adjuvant chemotherapy and a
disease free survival time of 6 months or more. The clin-
icopathological characteristics of patients were shown in
Table 1.
Follow up
All 152 patients were followed up to December 31, 2015.
The median follow-up time was 82 months. At the end
of the follow-up period, 117 patients were still alive.
Among them, 46 patients had had relapses and 106 pa-
tients had not; all of the relapses were confirmed by
histopathology.
Peripheral serum collection and serum CA125 detection
Peripheral blood 2 ml was collected under written consent
from the patients in the morning after fasting pre-
treatment, post-treatment, during each chemotherapy, and
at times of recurrence. The samples were stored at 4 °C for
2 h, centrifuged at 3000 rpm for 5 min, then the super-
natant was collected and stored at −80 °C. A radio-
immunoassay was used to detect the concentration of
serum CA125, performed according to the manufacturer’s
specifications; the normal value range is ≤ 35 U/ml.
Statistical analysis
SPSS19.0 statistical software was used to analyze the
data. Categorical data were analyzed by χ2 tests and con-
tinuous data were analyzed by rank-sum tests. The sur-
vival rate in different groups was analyzed by log-rank
tests and stratification analyses were performed with
stratified chi-square tests. Correlation analyses were per-
formed using Pearson’s correlation test, and multivariate
analyses were performed using Cox regression models.
P < 0.05 was defined as statistically significant.
Results
The relationship between serum CA125 levels and
progression-free survival (PFS) and OS
When patients with pre-treatment serum CA125 level ≤
35 U/ml were compared with those with serum CA125
level > 35 U/ml, the median PFS was 52 and 36 months,
respectively, P = 0.032, a statistically significant differ-
ence. The median OS of these 2 groups was 54 and
39 months, respectively, P = 0.023, a statistically signifi-
cant difference (see Fig. 1).
Age, stage, and pathological types were used to per-
form a stratification analysis of each pre-treatment
serum CA125 level, comparing the survival rate and cal-
culating the odds ratio and 95 % confident interval dis-
tribution according to the results of the stratification
analysis. As shown in Fig. 2, the survival rate in each
serum CA125 level stratum has no significant difference
by age, stage, or pathological type (P > 0.05).
The relationship between prognosis and the extent and
speed of serum CA125 decrease after treatment
When comparing patients with a post-treatment loga-
rithmic decrease (shown as Fig. 3) of serum CA125
with patients without a non-logarithmic decrease, the
median PFS was 45 and 34 months, respectively, P =
0.043, a statistically significant decrease. The median
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OS was 61 and 38 months, respectively, P = 0.038, a
statistically significant decrease (see Fig. 4).
We explored the relationship between patient out-
come and the speed of serum CA125 decrease. Com-
paring patients in whom serum CA125 decreased to
normal within a month with those that took more
than a month, the median PFS was 45 and 38 months,
respectively, P = 0.047, a statistically significant differ-
ence. The median OS was 56 and 38 months, respect-
ively, P = 0.029, a statistically significant difference
(see Fig. 5).
Multivariate Cox regression analysis was used to
analyze the serum CA125 levels at pre-treatment, the
extent and speed of serum CA125 decrease after treat-
ment, and the increased level of serum CA125 in re-
lapses. The results show that levels before treatment and
decreased speed of decline of serum CA125 levels after
treatment were independent factors (see Table 2).
The relationship between serum CA125 levels
(biochemical recurrence) and finding lesions by imaging
examination
Fifty-one patients were diagnosed positive for a recur-
rence by imaging examination. Among them, 40 patients
were true positive and 11 patients were false positive.
Twenty-one patients (52.5 %) had serum CA125 ≥ 100
U/ml, 14 patients (35.0 %) had serum CA125 between
35–100 U/ml, and 5 patients (12.5 %) had serum
CA125 ≤ 35 U/ml. Comparing patients with serum
CA125 ≥ 100 U/ml with those with serum CA125 be-
tween 35–100 U/ml, P = 0.397, the difference was not
statistically significant. Comparing patients with serum
CA125 ≥ 100 U/ml with patients with serum CA125 ≤
35U/ml, P = 0.003, the difference was statistically signifi-
cant. Comparing patients with serum CA125 between
35–100 U/ml and those with serum CA125 ≥ 100 U/ml,
P = 0.041, the difference was statistically significant. As
Fig. 1 Relationship between levels of pre-treatment serum CA125 concentration and PFS, OS
Fig. 2 Odds ratio of survival rate and 95 % confidence distribution
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we can see in Table 3, mainly patients with serum
CA125 ≥ 100U/ml were diagnosed true positive by im-
aging examination and those diagnosed false positive by
imaging examination were mainly patients with serum
CA125 ≤ 35 U/ml.
Correlation analysis found that the average increased
level of serum CA125 at relapse was 116.28 U/ml. The
average time between serum CA125 level increase to
finding a recurrent lesion by physical examination or im-
aging examination was 122 days. The correlation coeffi-
cient of serum CA125 level increases and tumor
recurrence time was –0.674; i.e., the average increased
levels of CA125 in relapsed patients and the average
time of displaying recurrent lesions were negatively cor-
related. The higher the serum CA125 level was, the
shorter the time before the recurrent lesion was detected
(see Fig. 6).
The significance of the change pattern of serum CA125
level post-treatment for diagnosing recurrence of EOC
In all of the patients, 35 U/ml was defined as the critical
cutoff value for recurrence. Serum CA125 in 45 patients
was > 35 U/ml, and among them 31 patients were diag-
nosed by pathology; in 107 patients, serum CA125 was ≤
35 U/ml, and among them 15 patients were diagnosed
by pathology. The area under the ROC curve was 0.879
for diagnosing an EOC recurrence by using serum
CA125, and the diagnostic sensitivity and specificity was
67.39 and 86.79 %, respectively. The positive predictive
value was 0.69, the negative predictive value was 0.86,
the positive likelihood ratio was 5.10, and the negative
likelihood was 0.38 (see Fig. 7).
Discussion
The significance of the change pattern of serum CA125
level post-treatment for judging recurrences of EOC
The clinical data statistical analysis shows that there was
a relationship between patient outcomes and serum
CA125 levels before treatment and the extent and speed
of serum CA125 decrease after treatment. The outcomes
of patients with pre-treatment serum CA125 ≤ 35 U/ml
were better than those with serum CA125 > 35 U/ml.
The outcomes of patients with serum CA125 logarith-
mic decrease or decrease to normal within a month after
treatment were also better than those with a non-
logarithmic decrease, or taking more than a month to
decrease to normal.
Comparing patients with a serum CA125 logarithmic de-
crease and those with a non-logarithmic decrease, the me-
dian PFS was 45 and 34 months, respectively, P = 0.043, a
Fig. 3 Typical curve of CA125 logarithmic decrease
Fig. 4 Comparison of PFS, OS between different serum CA125 decrease patterns after treatment
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statistically significant difference. Results of multivariate
Cox regression analysis showed that CA125 levels before
treatment and a decreased speed in decline of serum
CA125 after treatment were independent prognostic
factors.
The serum CA125 level pre-treatment is closely re-
lated to tumor size. The higher the serum CA125 levels,
the larger the tumor lesions are, and the deeper and
wider the tumor infiltrates, making cytoreductive surgery
(CRS) harder. Whether CRS is successful or not has a
great influence on continued treatment, so it affects
prognosis. Eltabbakh et al. [2] explored influence factors
of optimal CRS and found that 72 patients with ad-
vanced ovarian cancer could have an optimal CRS if
serum CA125 was ≤ 500 U/ml. Vorgias et al. [3] analysed
the relationship between the preoperative CA125 levels
of 426 patients with Stage III/IV ovarian carcinoma and
the surgical outcome. The data indicated preoperative
CA125 is a good predictor for optimal CRS. The area
under curve of the ROC curve was 0.89, 98 % C.I.
= [0.828–0.952], indicating very good discriminating cap-
ability. The level of 500 IU/ml was found to have the
most predictive power. The sensitivity of CA125 at that
level was 78.5 %, the specificity 89.6 %, the positive pre-
dictive value 84.2 %, the negative predictive value 85.4 %
and its accuracy 85 %. Furthermore, the likelihood ratio
for correct discrimination between optimal and sub-
optimal CRS, dropped sharply from 6.33, 95 % C.I.
[5.19–10.91] at the level of 500 IU/ml to 0.58, 95 % C.I.
[0.21–1.63] at the level of 600 IU/ml. The data indicate
that the best threshold for this prediction proved to be
500 IU/ml. These patients may be candidates for neo-
adjuvant chemotherapy treatment.
There is a close relationship between post-treatment
serum CA125 levels and the size of residual lesions after
CRS. The larger the residual size, the slower the serum
CA125 level decreases. If the serum CA125 level does
not decrease rapidly after CRS it always means that the
residual lesions are large, the prognosis is worse, and the
patients can relapse easily. The speed of serum CA125
decrease to normal after treatment has significance for
diagnosing relapse to some degree. Patients with a high
pre-treatment level of serum CA125 have a better prog-
nosis if their serum CA125 decreases to normal rapidly
after surgery, while patients with a low pre-treatment
level of serum CA125 have a worse prognosis if their
Fig. 5 Comparison of PFS, OS between different speeds of serum CA125 decrease after treatment
Table 2 Cox regression analysis





Levels before treatment 1.136 3.274 0.025
Decrease speed after treatment 2.164 6.213 0.002
Table 3 The relationship between serum CA125 levels in
recurrences and finding lesions by imaging examinations
Serum CA125 levels
after treatment (U/ml)
Imaging (CT, MRI) diagnosis
Positive (case %) Negative (case %) P
≥100a, b 21 (52.5 %) 2 (18.2 %) 0.397a
35–100a, c 14 (35.0 %) 3 (27.3 %) 0.003b
≤35b, c 5 (12.5 %) 6 (54.5 %) 0.041c
Total 40 11
a: Comparison between patients with CA125 ≥ 100 U/ml and patients with
CA125 35–100 U/ml
b: Comparison between patients with CA125 ≥ 100 U/ml and patients with
CA125 ≤ 35 U/ml
c: Comparison between patients with CA125 35–100 U/ml and patients with
CA125 ≤ 35 U/ml
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serum CA125 does not decrease to normal rapidly after
surgery.
Systemic, regular, and full doses of chemotherapy are
necessary, and after chemotherapy the serum CA125
levels decrease. The half-life of serum CA125 can show
the changing rate of serum CA125 in early treatment by
chemotherapy and we can judge the prognosis according
to the half-life of serum CA125. Na et al. [4] showed
that patients with a serum CA125 half-life of more than
20 days (group 1) have a 3.2 times greater risk of recur-
rence than those with a serum CA125 half-life of less
than 20 days (group 2). The average relapse-free time of
group 1 was 11 months and that of group 2 was
43 months. Digant et al. [5] Reported that reduction in
CA125 after 3 months of therapy is associated with bet-
ter overall survival in ovarian cancer. Patients without a
significant decline in CA125 after 3 months of therapy
have a particularly poor prognosis.
Fig. 6 The scatter diagram of the average time of serum CA125 level increase to finding the recurrent lesion
Fig. 7 ROC of CA125 for diagnosing recurrences
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The significance of the change pattern of serum CA125
levels post-treatment for diagnosing recurrence of EOC
Our data show that the serum CA125 level of most re-
lapsed patients would rises. The average increased level
is 116.28 U/ml; the average time between an increase in
serum CA125 and detection of the recurrent lesion by
physical examination or imaging examination is 122 days,
and there is a relationship between the pattern of serum
CA125 level increases and finding the recurrent lesion
by physical or imaging examination. The increased level
of serum CA125 has a negative correlation with the time
before finding the recurrent lesion. The higher and faster
serum CA125 increases, the shorter the time to find the
recurrent lesion by physical or imaging examination.
These results are similar to the results of Levy [6]. Levy’s
team observed the change pattern of serum CA125 in
relapsed patients with EOC and found that PFS or OS of
relapsed patients with serum CA125 that increased
slowly are longer than for those whose serum CA125 in-
creased rapidly. In this study, the area under the ROC
curve was 0.879, and the sensitivity and specificity for
diagnosing recurrence were 67.39 and 86.79 %, respect-
ively. The sensitivity of diagnosing recurrence was low,
may be because of the following reasons: (1) The recur-
rent tumors are small and the levels of antigen may be
too low to activate an antibody response. (2) There is a
fibrous envelope around the cancer tissue which might
block the release of the antigen into the blood circula-
tion. (3) Chemotherapy drugs may have changed the
biological behavior of the cancer cells. Some studies
found that in patients with negative serum CA125, the
negative rate of second surgical exploration was as high
as 43.8 %. A previous study confirmed that serum
CA125 is positive if the patients suffer from pelvic in-
flammation, endometriosis, pleura and peritoneum
pathological changes, or liver cancer.
Solutions for EOC patient with simple serum CA125
increases post-treatment
There is still a controversy about whether patients
should receive treatment when their serum CA125 in-
creases alone post-treatment [7, 8]. A prospective multi-
center clinical trial showed that patient outcomes were
not improved if chemotherapy was given when serum
CA125 increased, and it reduced quality of life [9]. This
may be because the tumor cells were not in the prolifer-
ation period and were not sensitive to chemotherapy
drugs.
Conclusions
CA125 is the most widely used tumor marker in ovarian
cancer for diagnosis, monitoring disease and judging
prognosis. Our study indicates that levels before treat-
ment and decreased speed of decline of serum CA125
after treatment were independent factors. There is a
negative correlation between pre-treatment CA125 level
and prognosis, the sooner decrease of CA125 levels
post-treatment the better prognosis are. When the
serum CA125 levels after treatment increase over to
116.28 U/ml comprehensive examination would be used
to identify whether recurrences occur. The average time
from serum CA125 increase to detection of a recurrent
lesion by physical or imaging examination was about
3 months. It is not recommend chemotherapy when
patients serum CA125 increased alone after post-
treatment. So It is important to monitor the change
pattern of serum CA125 post-treatment for judging
prognosis and diagnosing recurrences of EOC.
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